Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat
Open Access
- 8 May 2026
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70259
Abstract
Mitiperstat is a novel myeloperoxidase inhibitor being investigated for the treatment of heart failure, metabolic dysfunction‐associated steatohepatitis, and chronic obstructive pulmonary disease. Pharmacokinetic data from five clinical trials were used to develop a mitiperstat population pharmacokinetics (popPK) model. In total, 2856 plasma samples from 128 mitiperstat‐treated participants were collected during the first‐in‐human single‐ascending dose (SAD) study; multiple‐ascending dose studies (MAD) in healthy volunteers, including healthy Japanese and Chinese volunteers (JCMAD); the phase 2a SATELLITE study in patients with heart failure with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF); and from a study in patients with severe renal impairment. The mitiperstat concentration‐time data were pooled and analyzed with the software NONMEM. The covariates considered in this analysis were baseline estimated glomerular filtration rate (eGFR), baseline body weight, baseline body mass index, sex, race (Asian or non‐Asian), age, disease status (healthy volunteers or patients with HFpEF/HFmrEF), and formulation (oral suspension or tablet). The final popPK model is a two‐compartment model with first‐order absorption and linear elimination. Baseline body weight, disease status, Asian race, and eGFR were identified as significant covariates for apparent clearance, and age was identified as a significant covariate for apparent central volume of distribution. The final model predicts that severe renal impairment and lower body weight have the largest impact on exposure. Exposure to mitiperstat increased as eGFR declined. This popPK model constitutes an important step toward optimizing doses for efficacy and safety in the different mitiperstat development programs. Trial Registration: ClinicalTrials.gov : NCT02712372Keywords
Funding Information
- AstraZeneca
This publication has 17 references indexed in Scilit:
- Role of myeloperoxidase in inflammation and atherosclerosis (Review)Biomedical Reports, 2022
- Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection FractionClinical and Translational Science, 2020
- Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteersBritish Journal of Clinical Pharmacology, 2019
- Targeting myeloperoxidase in inflammatory atherosclerosisEuropean Heart Journal, 2018
- Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaqueEuropean Heart Journal, 2018
- Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney FunctionCirculation: Heart Failure, 2017
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Myeloperoxidase, modified lipoproteins, and atherogenesisJournal of Lipid Research, 2009
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005
- Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in HumansCirculation, 2004